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Available online 18 July 2016Lysophosphatidic acid receptor 1 (LPA1) is a druggable target for treating pulmonary inﬂammatory diseases.
However, themolecular regulation of LPA1 stability, a factor that critically impacts its biological activity, remains
largely unknown. Here we identify two enzymes that regulate the balance of LPA1 ubiquitination and
deubiquitination. Ubiquitin E3 ligase Nedd4L targets LPA1 for its site speciﬁc ubiquitination and degradation in
the lysosome. Nedd4L negatively regulates LPA-LPA1-mediated cytokine release. The stability of LPA1 is up-reg-
ulated by ubiquitin-speciﬁc protease 11 (USP11), which deubiquitinates LPA1 and enhances LPA1-mediated pro-
inﬂammatory effects. LPA1 is associatedwith USP11 in quiescent cells, while LPA treatment triggers LPA1 dis-as-
sociation with USP11 and in turn binding to Nedd4L. Knockdown or inhibition of USP11 reduces LPA1 stability,
levels of LPA1, and LPA1-CD14 interaction complex; thereby diminishing both LPA- and LPS-induced inﬂamma-
tory responses and lung injury in preclinicalmurinemodels. Thus, our ﬁndings identify an ubiquitin E3 ligase and
a deubiquitinating enzyme responsible for regulation of LPA1 stability and biological activities. This study pro-
vides potential targets for the development of anti-inﬂammatory molecules to lessen lung injury.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Lung injury1. Introduction
In the United States, approximately 200,000 people suffer annually
from acute lung injury (ALI) and the acute respiratory distress syn-
drome (ARDS), with a high mortality rate ranging from 30 to 40%
(Rubenfeld et al., 2005). Acute respiratory infection commonly elicits a
cytokine storm, leading to epithelial and endothelial barrier disruption,
edema, and often respiratory failure. Lipopolysaccharide (LPS), a bacte-
rial endotoxin, induces a strong cytokine storm through its receptor
complex composed of toll-like receptor 4 (TLR4) and CD14 (Lu et al.,
2008; Ojaniemi et al., 2003; Park and Lee, 2013). In addition to binding
to TLR4, CD14 associates with other cell surface proteins, such as surfac-
tant protein C (Augusto et al., 2003), to modulate LPS-induced inﬂam-
matory responses. Our recent study revealed that CD14 interacts with
the lysophosphatidic acid receptor 1 (LPA1), which belongs to G-pro-
tein-coupled receptors (GPCRs) (Zhao et al., 2011)., University of Pittsburgh, 3459
d States.
upmc.edu (Y. Zhao).
B.V. This is an open access articleLPA1 is highly expressed in lung tissue and contributes to the path-
ogenesis of lung injury through binding to LPA (Zhao and Natarajan,
2013; Lin et al., 2010), a naturally occurring bioactive lipid, and its inter-
action with CD14 (Zhao et al., 2011). We have shown that LPA1-modu-
lated signals are involved in release of chemotactic factor interleukin 8
(IL-8) (Saatian et al., 2006; Cummings et al., 2004; Zhao et al., 2005),
neutrophil inﬂux to the lungs (He et al., 2009), and airway epithelial hy-
perplasia (Funke et al., 2012). The protein level of LPA1 is increased in
lung inﬂammatory disorders, including asthma (Georas et al., 2007),
pulmonary ﬁbrosis (Tager et al., 2008), and ALI (Zhao et al., 2011).
LPS- or bleomycin-induced lung injury is diminished in LPA1-deﬁcient
mice (Zhao et al., 2011; Tager et al., 2008); therefore, LPA1 is a potential
target for pharmaceutical treatment of lung injury. However, themolec-
ular regulation of LPA1 has not been well studied.
Themono-ubiquitination-lysosome systemdegrades themajority of
cell surface receptors including GPCRs (Marchese and Trejo, 2013;
Marchese et al., 2003; Shenoy et al., 2008; Henry et al., 2012; Xiao and
Shenoy, 2011). Three enzyme complexes (E1, E2, and E3) are involved
in protein ubiquitination. E3 ubiquitin ligases facilitate the covalent at-
tachment of ubiquitin to speciﬁc lysine residue(s) within target pro-
teins. The E3 ubiquitin ligase for LPA1 has not been reported. Nedd4L,
a member of HECT class of E3 ubiquitin ligase has been known tounder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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epithelial sodium channel (ENaC) (Kamynina et al., 2001), Smad2, and
Smad3 (Gao et al., 2009). Here we demonstrate that the ubiquitin E3 li-
gase Nedd4L mediates LPA1 ubiquitination and lysosomal degradation,
therefore limiting LPA1-modulated signaling.
Protein ubiquitination is reversible; removal of ubiquitin chains
from target proteins is mediated by deubiquitinating enzymes. We
have shown that ubiquitin-speciﬁc protease (USP) 14 modulates I-κB
levels (Mialki et al., 2013). Little is known about the role of USPs in
the regulation of GPCR stability. USP11, a ubiquitous protein in various
human cells, has been shown to enhance TGFβ receptor (ALK5) stability
(Al-Salihi et al., 2012) and regulate DNA repair (Wiltshire et al., 2010).
The current study reveals that LPA1 is a substrate for USP11, and inhibi-
tion of USP11mitigates lung injury through reduction of LPA1 levels and
LPA1-CD14 pathway.
2. Materials and Methods
2.1. Cells and Reagents
Murine lung epithelial (MLE12) cells (from ATCC) were cultured
with HITES medium containing 10% fetal bovine serum (FBS) and anti-
biotics at 37 °C in 5% CO2. Primary culture of human bronchial cells
(HBEpCs) (from Lonza, Baltimore, MD) was conducted using medium
supplemented with growth factors provided by Lonza. V5 antibody,
mammalian expressional plasmid pcDNA3.1-His-V5-topo, and
Escherichia coli Top10 competent cells were from Life technologies
(Grand Island, NY). P-p38 MAPK, p38 MAPK, p-IκB, Nedd4L, HA tag,
and ubiquitin antibodies were from Cell Signaling (Danvers, MA).
LPA1 and LPA2 antibodies were from LifeSpan BioScience, Inc. (Seattle,
WA). Cycloheximide (CHX, 3-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-
hydroxyethyl]glutarimide), leupeptin (Acetyl-Leu-Leu-Arg-al), lipo-
polysaccharide (LPS), β-actin and myc tag antibodies were from Sigma
(St. Louis, MO). MG-132 (Z-L-Leu-D-Leu-L-Leu-al) and baﬁlomycin A1
(C35H58O9) were from EMD Chemicals (Philadelphia, PA).
Immunobilized protein A&G beads, control IgG, p-Erk1&2, Erk1&2, and
USP11 antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). All materials in highest grades used in the experiments are com-
mercially available.
2.2. Plasmid and shRNA Transfection
Human LPA1, human NEDD4L, or human USP11 cDNA, and mutants
were inserted into pCDNA3.1-V5-His-Topo vector, pCDNA3.1-HA vec-
tor, or pCDNA3.1-myc vector. All the primerswere designed using Prim-
er3 or QuickChange Primer Design Tool (Agilent Technologies Inc.)
software. Over-expression of plasmids in MLE12 cells was performed
using the Lonza nucleofector system. Over-expression of plasmids in
HBEpCs was performed using FuGENE HD reagent (Promega, Madison,
WI).
2.3. Preparation of Protein Extracts and Immunoblotting
After indicated treatments, cells were lysed in 1× lysis buffer (Cell
signaling). Equal amount of total protein were subjected to SDS-PAGE
gel, transferred to nitrocellulose, and then immunoreacted with prima-
ry antibody, followed by secondary antibody.
2.4. Co-Immunoprecipitation
Equal amounts of protein were incubated with primary antibody for
overnight at 4 °C, followed by adding protein A&G beads for additional
2 h in room temperature. The beads were precipitated by centrifugation
at 1000g for 2 min, and then were rinsed with PBS for 3 times. Proteins
on the beads were eluted by boiling in SDS sample buffer.2.5. Immunostaining
MLE12 cells were cultured in glass-bottom dishes and ﬁxed with
3.7% formaldehyde for 20 min. Permeabilization in 0.1% Triton-100 for
1 min was performed for determining localization of LPA1-V5, LPA1-
myc, HA-Nedd4L, or USP11-V5. Cellswere exposed to primary antibody,
followed by incubation with ﬂuorescence-labeled secondary antibody.
Immunoﬂuorescent cell imaging was performed using a Zeiss LSM 510
confocal microscope.
2.6. Reverse Transcription (RT) Realtime PCR
Cells were collected after indicated treatment, and then total RNA
was extracted using Trizol reagent from Life Technologies. 1 μg of RNA
was used for reverse transcription reaction to generate cDNA. Realtime
PCR was performed using Bio-Rad Ssofast Evagreen supermix reagent
with synthesized cDNA as template. PCR primers were designed for de-
tecting human IL-8, IL-6, and mouse KC gene.
2.7. Animals
C57/BL6mice (6–8/group) were given intratracheal (i.t.) LPS (2mg/
kg body weight) for 24 h. BAL ﬂuid was collected for cytokine analysis
using ELISA. Mouse Usp11 shRNA was inserted into a pLVX-IRES vector
(Clontech); Lenti-shUSP11 viral and control viral vectors were generat-
ed by using a lentivirus packaging system (Clontech). C57/BL6 mice
were given i.t. Lenti-control or Lenti-USP11 shRNA (109 plaque-forming
units/mouse) for 7 days prior to i.t. inoculation with LPS (2 mg/kg
weight) for 24 h. BAL ﬂuid was collected for cytokine assays and lung
tissues were ﬁxed for hematoxylin and eosin (H&E) staining. To deter-
mine the effect of MX on lung inﬂammation, C57/BL6 were given i.t.
MX (0.25 mg/kg body weight) prior to LPS challenge, and then BAL
ﬂuids and lung tissueswere randomly andblindly analyzed as described
above. All animal procedures in this studywere performed in adherence
with theNational Institute of HealthGuidelines on the use of Laboratory
Animals and have been approved by the Institutional Animal Care and
Use Committee of the University of Pittsburgh.
2.8. Statistical Analysis
All resultswere subjected to statistical analysis usingMicrosoft Excel
or ANOVA, and, wherever appropriate, the data were analyzed by
Student's t-test and expressed as means ± SD. Data were collected
from at least three independent experiments, and p b 0.05 was consid-
ered signiﬁcant.
3. Results
3.1. Site Speciﬁc Ubiquitination of LPA1 Promotes LPA1 Degradation
Ligand-induced receptor degradation plays a negative feedback loop
to attenuate membrane receptor signaling. To investigate themolecular
regulation of LPA1 degradation, murine lung epithelial (MLE12) cells
were treated with LPA, and protein levels of endogenous and over-
expressed V5-tagged LPA1 (LPA1-V5) were examined by immunoblot-
ting. As shown in Fig. 1a and b, LPA treatment reduces LPA1 levels in a
time dependent manner. As ubiquitination is a recognized signal for re-
ceptor degradation, we examined the whether LPA1 is ubiquitinated
and its role in LPA1 degradation. LPA1 ubiquitination was examined
by immunoprecipitation with an ubiquitin antibody, followed by LPA1
immunoblotting. LPA treatment induced mono-ubiquitination of LPA1
in 30min (Fig. 1c). To determinewhether LPA1 is degraded in the lyso-
some, the localization of LPA1-V5 was determined by immunoﬂuores-
cence staining. LPA1-V5 was co-localized with lysosome marker after
LPA treatment (Fig. 1d). Further, inhibition of lysosome function by
leupeptin or baﬁlomycin A1 impaired LPA-induced LPA1-V5
Fig. 1. LPA1 lysosomal degradation is mediated by site speciﬁc ubiquitination. a. MLE12 cells were treated with LPA (5 μM) for 0–2 h, cell lysates were then analyzed by immunoblotting
with LPA1 and β-actin antibodies. b. MLE12 cells were transfected with V5 tagged LPA1 (LPA1-V5) plasmid for 48 h, followed by LPA (5 μM, 0–60 min) treatment. Cell lysates were then
analyzed by immunoblotting with V5 and β-actin antibodies. c. MLE12 cells were treated with LPA (5 μM) for 0–2 h. Cell lysates were then subjected to immunoprecipitation with an
ubiquitin antibody, followed by LPA1 immunoblotting. Input lysates were analyzed by immunoblotting with LPA1 and β-actin antibodies. d. MLE12 cells grown on glass-bottom dishes
were transfected with LPA1-V5 plasmid for 48 h, followed by LPA (5 μM, 15 min) treatment. Cells were ﬁxed and stained with V5, lyso tracker, and 4′,6′-diamidino-2-phenylindole
(DAPI). LPA1-V5, green; lysosome, red; nuclei, blue. e. MLE12 cells were transfected with Lpa1-V5 plasmid for 48 h, and then cells were treated with or without leupeptin (100 μM) or
baﬁlomycin A1 (0.1 μM) for 1 h prior to LPA (5 μM, 0–60 min) treatment. Cell lysates were analyzed by immunoblotting with V5 and β-actin antibodies. f. MLE12 cells were
transfected with Lpa1-V5 or Lpa1k258r&k316r-V5 plasmid for 48 h, and then cells were treated with LPA (5 μM, 1 h). Cell lysates were subjected to immunoprecipitation with a V5
antibody, followed by ubiquitin and V5 immunoblotting. Input lysates were analyzed by immunoblotting with V5 and β-actin antibodies. g. Scheme shows LPA1 is ubiquitinated on
lysine 258 and 316 residues. Representative immunoblots were from at least three independent times.
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sosome. As ubiquitin mostly ligates to lysine residues (K) within the
substrates, we attempted to identify which lysine residue is the
ubiquitination site within LPA1. LPA1 contains two lysine residues
(K258 and K316) in the intracellular domains. We generated plasmids
coding signal lysine mutants (LPA1K258R or LPA1K316R) and double
lysine mutant (LPA1K258R&K316R). LPA1K258R&K316R was resistant
to LPA-induced ubiquitination and degradation (Fig. 1f), whileFig. 2. An E3 ubiquitin ligase, Nedd4L, induces LPA1 ubiquitination and degradation. a. MLE12 c
lysates were analyzed by immunoblotting with LPA1, HA, and β-actin antibodies. b. HBEpCs w
analyzed by immunoblotting with LPA1, LPA2, V5, and β-actin antibodies. c. MLE12 cells we
were analyzed by immunoblotting with V5, HA, and β-actin antibodies. d. MLE12 cells were co
48 h. Cell lysates were analyzed by immunoblotting with V5 and β-actin antibodies. e. MLE12
were analyzed by immunoblotting with LPA1, V5, and β-actin antibodies. f. MLE12 cells were
were treated with LPA (5 μM) for 1 h. Cell lysates were analyzed by immunoblotting with LP
Nedd4l shRNA for 72 h, and then cell lysates were subjected to immunoprecipitation with a
immunoblotting with LPA1, Nedd4L, and β-actin antibodies. Representative immunoblots werLPA1K258R or LPA1K316R had no effect on LPA1 stability (supplemen-
tal Fig. 1), indicating that both the lysine residues are necessary for LPA1
ubiquitination and stability. Mono-ubiquitination contributes to inter-
nalization of cell surface receptors. However, LPA induced internaliza-
tion of both LPA1-V5 and ubiquitination site mutants (supplemental
Fig. 2). The data suggests that ubiquitination at K258R&K316 regulates
LPA1 degradation (Fig. 1g), but it is not essential for LPA1
internalization.ells were transfected with HA-tagged Nedd4L (HA-NEDD4L, 0–4 μg) plasmid for 48 h. Cell
ere transfected with V5-tagged Nedd4L (NEDD4L-V5) plasmid for 48 h. Cell lysates were
re co-transfected with LPA1-V5 and HA-NEDD4L (0–2 μg) plasmids for 48 h. Cell lysates
-transfected with NEDD4L-V5 plasmid and LPA1-V5 or LPA1K258R&K316R-V5 plasmid for
cells were transfected with NEDD4L-V5 or NEDD4LC801A-V5 plasmid for 48 h. Cell lysates
transfected with control shRNA (Cont shRNA) or Nedd4l shRNA for 72 h, and then cells
A1, Nedd4L, and β-actin antibodies. g. MLE12 cells were transfected with Cont shRNA or
n ubiquitin antibody, followed by LPA1 immunoblotting. Cell lysates were analyzed by
e from at least three independent times.
Fig. 3. Nedd4L interacts with LPA1 on serine 319 residue. a. MLE12 cells were transfected with HA-Nedd4 or HA-Nedd4L plasmid for 48 h. Cell lysates were subjected to
immunoprecipitation with a LPA1 antibody, followed by HA and LPA1 immunoblotting. Input lysates were analyzed by immunoblotting with HA and β-actin antibodies. b. MLE12 cells
were transfected LPA1-V5 with or without HA-NEDD4L plasmid. Cell lysates were subjected to immunoprecipitation with a HA antibody, followed by V5 and HA immunoblotting. Input
lysates were analyzed by V5, HA, and β-actin antibodies. c. MLE12 cells grown on glass bottom dishes were co-transfected with LPA1-V5 and HA-NEDD4L plasmid for 48 h, and then
cells were ﬁxed and immunostained with V5 and HA antibodies. LPA1-V5, green; HA-Nedd4L, red; nuclei, blue. d. MLE12 cells were treated with LPA (5 μM) for 30 min, and then cell
lysates were subjected to immunoprecipitation with a LPA1 antibody, followed by Nedd4L and LPA1 immunoblotting. Input lysates were analyzed by Nedd4L immunoblotting. e.
MLE12 cells were transfected with LPA1-V5 or LPA1S319A-V5 plasmid for 48 h. Cell lysates were subjected to immunoprecipitation with a V5 antibody, followed by Nedd4L
immunoblotting. Input lysates were analyzed by immunoblotting with Nedd4L and β-actin antibodies. f. MLE12 cells were transfected with LPA1-V5, LPA1S319A-V5, or LPA1S331A-V5,
with or without HA-NEDD4L plasmids for 48 h. Cell lysates were analyzed by V5, HA, and β-actin antibodies. Representative immunoblots were from at least three independent times.
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Protein ubiquitination is mediated by a series of enzymatic reactions
in which ubiquitin E3 ligase is responsible for transferring ubiquitin to
the substrate. Over-expression of an E3 ubiquitin ligase, Nedd4L, re-
duced endogenous and over-expressed LPA1 levels in MLE12 (Fig. 2a,
c) and human bronchial epithelial cells (HBEpCs) (Fig. 2b), without al-
tering levels of LPA2 (Fig. 2b) and LPA1K258R&K316R (Fig. 2d). Inactive
mutant of Nedd4L (Nedd4LC801A) had no effect on LPA1 degradation
(Fig. 2e). Further, down-regulation of Nedd4L by nedd4l shRNA trans-
fection attenuated LPA1 degradation (Fig. 2f) and ubiquitination (Fig.
2g). This study elucidates Nedd4L mediation of LPA1 site speciﬁc
ubiquitination and degradation.
To investigate whether Nedd4L interacts with LPA1, HA-Nedd4L or
HA-Nedd4 (a Nedd4L isoform) over-expressing MLE12 cells were sub-
jected to LPA1 immunoprecipitation, followed by HA immunoblotting.
As shown in Fig. 3a, Nedd4L, not Nedd4, is associated with LPA1 (Fig.
3a). LPA1-V5 was also detectable in HA-Nedd4L immunoprecipated
complex from LPA1-V5 and HA-Nedd4L co-over-expressing cells (Fig.
3b). Nedd4L and LPA1 were co-localized on the plasma membrane as
well as in the cytoplasm (Fig. 3c). Further, we found that the association
between LPA1 and Nedd4L was increased in response to LPA treatment
(Fig. 3d). It is known that Nedd4L binds to proline-rich PY motif or ser-
ine residue of substrate; LPA1 has no canonical proline-rich PY motif,
but a serine 319 mutant of LPA1 (LPA1S319A) is unable to interact
with Nedd4L (Supplemental Fig. 3a), suggesting that serine 319 is aFig. 4.Nedd4L impairs LPA-LPA1 signaling. a. MLE12 cells were transfectedwithHA-nedd4l plas
were analyzed by immunoblotting with p-p38 MAPK, p38 MAPK, p-Erk1&2, Erk1&2, HA, and β
72 h, and then cells were treated with LPA (5 μM) for 0–60 min. Cell lysates were analyzed by
antibodies. Representative immunoblots were from at least three independent times. c. HBEp
LPA (1 μM) for 3 h. Cells were collected and IL-8 mRNA levels were analyzed by RT-realtime Ppotential Nedd4L binding site within LPA1. LPA1S319A, but not other
mutant (e.g. LPA1S331A), was resistant to LPA-induced receptor degra-
dation (Supplemental Fig. 3b).
3.3. Nedd4L Inhibits the LPA-LPA1 Pathway
To investigate the effect of Nedd4L on the LPA-LPA1 pathway,
MLE12 cells were transfected with HA-NEDD4L plasmid or Nedd4l
shRNA prior to LPA treatment. The phosphorylation of p38 MAPK and
Erk1& 2 by LPA were attenuated in HA-Nedd4L over-expressing cells
(Fig. 4a), while the phosphorylation was promoted in Nedd4L down-
regulating cells (Fig. 4b). LPA is a strong stimulator of IL-8 mRNA ex-
pression in HBEpCs (Saatian et al., 2006). Further, we found that HA-
Nedd4L attenuated LPA-induced IL-8 mRNA expression in HBEpCs
(Fig. 4c). This study reveals that Nedd4L inhibits the LPA-LPA1 pathway
through ubiquitination and reduction of LPA1 levels.
3.4. Deubiquitination of LPA1 by USP11 Increases its Stability
Ubiquitination is reversible and deubiquitination is catalyzed by a
family of deubiquitinating enzymes. We found that over-expression of
USP11, but not other deubiquitinating enzyme such asUSP5, attenuated
LPA-induced LPA1-V5 degradation (Fig. 5a). Over-expression of USP11
reversed LPA-induced LPA1 ubiquitination (Fig. 5b), suggesting that
USP11 stabilizes LPA1 through deubiquitination of the receptor. Co-im-
munoﬂuorescence staining revealed that USP11 was co-localized with
LPA1 in both the plasma membrane and cytoplasm (Fig. 5c); thismids (0–2 μg) for 48 h, and then cells were treatedwith LPA (5 μM) for 10min. Cell lysates
-actin antibodies. b. MLE12 cells were transfected with Cont shRNA or Nedd4l shRNA for
immunoblotting with p-p38 MAPK, p38 MAPK, p-Erk1&2, Erk1&2, Nedd4L, and β-actin
Cs were transfected with HA-NEDD4L plasmid for 48 h, and then cells were treated with
CR.
Fig. 5.USP11 deubiquitinates and stabilizes LPA1. a. MLE12 cells were co-transfectedwith LPA1-V5 andUSP11-V5 orUSP5-V5 plasmids for 48 h, and cells were treatedwith LPA (5 μM) for
0–60min. Cell lysateswere analyzed by immunoblottingwith V5 andβ-actin antibodies.b. MLE12 cellswere transfectedwith USP11-V5 plasmid for 48 h, and then cellswere treatedwith
LPA (5 μM) for 30min. Cell lysateswere subjected to immunoprecipitationwith an ubiquitin antibody, followed by LPA1 immunoblotting. Input lysateswere analyzed by immunoblotting
with LPA1, V5, and β-actin antibodies. c. MLE12 cells grown on glass bottom dishes were co-transfected with Usp11-V5 and Lpa1-myc plasmids for 48 h. Cells were ﬁxed and
immunostained with V5 and myc antibodies. USP11-V5, green; LPA1-myc, red; nuclei, blue. d. MLE12 cells were transfected with LPA1-V5 plasmid for 48 h, and then cells were treated
with LPA (5 μM) for 30 min. Cell lysates were subjected to immunoprecipitation with a V5 antibody, followed by USP11 immunoblotting. Input lysates were analyzed by
immunoblotting with USP11 and V5 antibodies. Representative immunoblots were from at least three independent times. e. Scheme shows that LPA treatment switches LPA1-USP11
complex to LPA1-Nedd4L complex.
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contrast to the LPA-increased in the association between LPA1 and
Nedd4L, LPA treatment reduced the interaction between LPA1 and
USP11 (Fig. 5d). Taken together, USP11 deubiquitinates and stabilizes
LPA1, and LPA-induced switching LPA1 association with USP11 to
Nedd4L plays a critical role in LPA1 ubiquitination and degradation
(Fig. 5e).
3.5. USP11 Promotes the LPA-LPA1 Signal Pathway
To investigate whether USP11 affects the LPA-LPA1 signal pathway,
MLE12 cells or HBEpCswere transfectedwithUSP11-HA orUsp11 shRNA
plasmid prior to LPA treatment. LPA-induced phosphorylation of p38
MAPK, Erk1&2, and I-κB were increased in USP11-HA over-expressing
MLE12 cells (Fig. 6a). Over-expression of USP11-HA enhanced LPA-in-
duced IL-8 gene expression in HBEpCs (Fig. 6b). Down-regulation of
USP11 attenuated LPA-induced phosphorylation of Erk1& 2, KC release,
and IL-6 gene expression in MLE12 cells (Fig. 6c-6e). The data indicates
that USP11 promotes LPA-LPA1 signaling and LPA-mediated cytokine
release by deubiquitinating and stabilizing LPA1.
3.6. USP11 Modulates the LPS Pathway by Increasing LPA1-CD14 Complex
Levels
It has been shown that LPA1 interacts with CD14, a LPS co-receptor,
in response to LPS treatment (Zhao et al., 2011). Inhibition or down-reg-
ulation of LPA1 attenuated LPS-induced signaling and cytokine release
in lung epithelial cells (Zhao et al., 2011; He et al., 2009). Here we
found that LPA treatment also induced the association between LPA1
and CD14 (Fig. 7a), which was promoted by over-expression of
USP11-HA. This suggests that USP11 may modulate the LPS pathway
through regulating LPA1 stability and levels of LPA1-CD14 complex. To
investigatewhether USP11modulates LPS-induced signaling, USP11 ex-
pression was down-regulated by usp11 shRNA transfection. Down-reg-
ulation of USP11 attenuated LPS-induced phosphorylation of Erk1& 2(Fig. 7b) and cytokine KC release (Fig. 7c) in MLE12 cells. It has been
shown that LPA1 deﬁcient mice exhibited signiﬁcant reduction of LPS-
induced inﬂammatory responses, compared to wild typemice, in a mu-
rine model of lung injury (Zhao et al., 2011). To investigate whether
down-regulation of USP11 exhibits protective effects against LPS-in-
duced lung injury, USP11 levels in themouse lungs were down-regulat-
ed by usp11 shRNA in a lentiviral vector delivery system (Fig. 7d).
Down-regulation of USP11 diminished LPS-induced neutrophil inﬂux,
BAL protein, IL-6 and KC levels (Fig. 7e-7h). This data provides a poten-
tial target in lessening inﬂammatory lung injury, and builds a molecular
basis for development of a therapeutic strategy to diminish endotoxin-
induced pro-inﬂammatory responses through inhibition of USP11.3.7. USP11 Inhibitor, Mitoxathrone, Reduces LPA1 Stability and Protects
LPS-Induced Lung Injury.
Mitoxantrone (MX), an anti-cancer drug, was reported to inhibit
USP11 (Burkhart et al., 2013). To conﬁrm the data from using usp11
shRNA, mitoxantrone was used to examine the role of USP11 in regula-
tion of LPA1 stability, the LPA-LPA1 pathway, and LPS signaling. MX in-
creased LPA-induced ubiquitination of LPA1 (Fig. 8a), and reduced the
mass of endogenous (Fig. 8b) and over-expressed LPA1 (Fig. 8c), with-
out altering LPA1 mRNA levels in MLE12 (Supplementary Fig. 4). Fur-
ther, MX pretreatment blocked LPA-induced phosphorylation of Erk1&
2, p38 MAPK, and I-κB (Fig. 8d), IL-8 gene expression, as well as LPS-in-
duced IL-8 release in HBEpCs, and KC gene expression in MLE12 (Fig.
8e–8g). To investigate whether MX exhibits anti-inﬂammatory effects
in LPS-induced lung injury, MX was intratracheally administrated into
mouse lungs prior to intratracheal LPS challenge. MX treatment signiﬁ-
cantly attenuated LPS-induced increases in levels of BAL protein, IL-6,
and KC, and neutrophil inﬂux into alveolar spaces (Fig. 8h–8k). This
data indicates that down-regulation or inhibition of USP11 protects
against lung inﬂammation via reduction of LPA1 stability and attenua-
tion of the LPA1-CD14 pathway.
Fig. 6.USP11 promotes LPA-LPA1 signaling. a. MLE12 cells were transfectedwith USP11-HA plasmid (0–2 μg) for 48 h, and then cells were treatedwith LPA (5 μM) for 10min. Cell lysates
were analyzed by immunoblottingwith p-p38MAPK, p38MAPK, p-Erk1&2, Erk1&2, p-IκB, HA, andβ-actin antibodies. Representative immunoblots were from at least three independent
times. b. HBEpCs were transfected with USP11-HA plasmid for 48 h, and then cells were treated with LPA (1 μM) for 3 h. Cells were collected and IL-8mRNA levels were examined by RT-
realtime PCR. c. MLE12 cells were transfected with Usp11 shRNA for 72 h, and then cells were treated with LPA (5 μM) for 10 min. Cell lysates were analyzed by immunoblotting with p-
Erk1&2, Erk1&2, and HA antibodies. Representative immunoblots were from at least three independent times. d. MLE12 cells were transfected with usp11 shRNA for 72 h, and then cells
were treated with LPA (5 μM) for 6 h. Cell culture supernatants were collected and KC levels in the media were analyzed by Elisa. The expression of USP11 was determined by
immunoblotting with USP11 and β-actin antibodies (insert). e. HBEpCs were transfected with USP11 shRNA for 72 h, and then cells were treated with LPA (1 μM) for 3 h. Cells were
collected and IL-6 mRNA levels were analyzed by RT realtime PCR.
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GPCR is a large family of cell surface receptors, which contributes to
the pathogenesis of a variety of inﬂammatory diseases, and is widely
targeted in drug discovery. As most GPCRs are ubiquitously expressed
in human cells, antagonists of GPCRs may cause unexpected side effects
due to complete inhibition of the GPCR pathway (Giulio Innamorati et
al., 2011). Thus, there is an unmet need to test an advanced strategy
that will suppress GPCR protein stability with limited off-target effects,
without completely inhibiting the target. Ubiquitination of cell surface
receptors regulates their stability, thus mediating downstream signal-
ing of the receptors. LPA1 is a well characterized GPCR as its expression
and it-mediated pathways are related to the pathogenesis inﬂammatory
lung diseases and tumors (Tager et al., 2008; Saatian et al., 2006; Zhao et
al., 2011; Lee et al., 2015), however, its stability has not been investigat-
ed. The current study reveals that LPA1 ubiquitination and degradation
is mediated by E3 ubiquitin ligase Nedd4L, which is reversed by
deubiquitinating enzyme USP11. This study reveals that upon stimula-
tion by an agonist, a GPCR switches its association with the
deubiquitinating enzyme (stabilizer) to the ubiquitin E3 ligase (degrad-
er), causing its ubiquitination and degradation. The discovery of themo-
lecular regulation of LPA1 stability will further lead to development of a
unique strategy to attenuation of LPA1 pathway through inhibition of
USP11.
LPA1 is ubiquitously expressed in mammalian cells, and it contains
an extracellular domain, three extracellular loops, seven transmem-
brane domains, three intracellular loops, and C-terminal tail (Chrencik
et al., 2015;Murph et al., 2008). Recent studies have revealed that intra-
cellular trafﬁcking of LPA1 determines the levels of LPA1 on the cell sur-
face (Murph et al., 2008; Zhao et al., 2014). β-arrestin- and clathrin-
dependent endocytosis mediate LPA1 internalization(Urs et al., 2005),
while heat shock protein regulates LPA1 trafﬁcking from the endoplas-
mic reticulum to the plasma membrane (Zhao et al., 2014; Dong et al.,2007). In addition to intracellular trafﬁcking, the receptor stability on
the cell surface determines receptor-mediated biological functions. Re-
duction of stability of sphingosine-1-phopshoate receptor 1 (S1P1),
which belongs to the same superfamily as LPA1, leads to endothelial
barrier dysfunction (Oo et al., 2011). The current data indicates that
LPA1 is a substrate of Nedd4L, and that Nedd4L diminishes LPA1 stabil-
ity, as well as LPA-induced signals and cytokine release. LPA1 is mono-
ubiquitinated at lysine 258 and 316, which are localized in the third in-
tercellular loop and C-terminal tail, separately. This data is consistent
with the emerging evidence showing that mono-ubiquitination of
membrane receptors leads to receptor lysosomal degradation. Though
several studies indicate that mono-ubiquitination is an internalization
signal for membrane proteins, such as α-factor receptor (Lucero et al.,
2000; Terrell et al., 1998), however, LPA-induced LPA1 internalization
is not dependent on its ubiquitination at K258 and K316 residues, as a
mutant with both lysine residues (LPA1K258R&K316R) internalizes
the same as LPA1 wild type in the setting of LPA treatment. Similarly,
the ubiquitination of S1P1 regulates its degradation without affecting
its internalization, suggesting that ubiquitination is not essential for
GPCR internalization (Oo et al., 2007). Taken together, LPA1 is
ubiquitinated in response to agonist ligation, which is catalyzed by
Nedd4L E3 ligase. The ubiquitination of LPA1 causes its lysosomal degra-
dation and limits LPA1-mediated cytokine release. It is known that
Nedd4L contributes to the pathogenesis of lung inﬂammatory diseases
(Kimura et al., 2011; Boase et al., 2011). Nedd4L knockout mice exhibit
respiratory distress and cystic ﬁbrosis-like disease (Boase et al., 2011;
Rotin and Staub, 2012).Most studies have been focusing onNedd4L reg-
ulation of ENaC stability (Kimura et al., 2011; Rotin and Staub, 2012).
Recent studies suggest that LPA1 plays a critical role in the pathogenesis
of pulmonary ﬁbrosis, as knockdown or inhibition of LPA1 lessens prog-
ress of pulmonary ﬁbrosis (Swaney et al., 2010; Castelino et al., 2011).
This study provides evidence that Nedd4L regulates LPA1 stability, sug-
gesting that the anti-ﬁbrotic effect of Nedd4L is through targeting both
Fig. 7.USP11 promotes LPA1-CD14 interaction and LPS-induced lung inﬂammation. a. MLE12 cells were transfectedwith USP11-HA plasmid for 48 h, and then cells were treatedwith LPA
(5 μM) for 30 min. Cell lysates were subjected to immunoprecipitation with LPA1 antibody, followed by CD14 and LPA1 immunoblotting. Input lysates were analyzed by immunoblotting
with CD14, HA, LPA1, and β-actin antibodies. b. MLE12 cells were transfected with usp11 shRNA for 72 h, and then cells were treated with LPS (10 μg/ml) for 30 min. Cell lysates were
analyzed by immunoblotting with p-Erk1&2, Erk1&2, and USP11 antibodies. Representative immunoblots were from at least three independent times. c. MLE12 cells were transfected
with Usp11 shRNA for 72 h, and then cells were treated with LPS (10 μg/ml) for 3 h. Cell culture supernatants were collected and KC levels in the media were analyzed by Elisa. d–h.
C57/BL6 mice (6–8/group) were intratracheally infected with control lentivirus (Lenti cont, 1 × 109 cfu/mice) or lentiviral vector carrying usp11 shRNA (Lenti USP11 shRNA Lenti cont,
1 × 109 cfu/mice) for 7 days, followed by i.t. administration with LPS (2 mg/kg body weight) for 24 h. Lung tissue lysates were analyzed by immunoblotting with USP11 and β-actin
antibodies (d). Lung tissue were ﬁxed and stained with H&E (e). BAL was collected, and then protein levels were examined by protein assay (f), IL-6 (g), and KC (h) were examined
by Elisa.
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lung injury has been revealed (Boase et al., 2011). Here, we reveal that
Nedd4L attenuates LPA-induced IL-8 release, suggesting Nedd4L may
have an anti-inﬂammatory property through regulating LPA1 signaling.
Most studies have been focused on investigating themolecular con-
trol of GPCR ubiquitination by identifying the E3 ubiquitin ligase, while
the little information is available for deubiquitination of GPCR by
deubiqutinating enzymes. Here we report that a deubiquitinating en-
zyme, USP11, promotes LPA1 stability by reduction of LPA1
ubiquitination, resulting in enhanced LPA-LPA1 signal pathway. USP11
has been known to regulate stability of ALK5 (Al-Salihi et al., 2012)
and promyelocytic leukemia protein (Wu et al., 2014). This report re-
veals a role of USP11 in the regulation of GPCR stability. An important
discovery in this study is that a change of association of LPA1 with
USP11 to Nedd4L is triggered by ligand binding. The results provide a
model for ubiquitination related enzymes regulation of substrate stabil-
ity by switching their interaction with substrate. It is this switch be-
tween deubiquitination enzyme-GPCR to E3 ubiquitin ligase-GPCR
which determines the degree of ubiquitination and degradation of
GPCR. The serine 319 was identiﬁed as the Nedd4L binding site in
LPA1, while the USP11 binding site in LPA1 and how ligand treatment
shifts the LPA1 binding fromUSP11 to Nedd4L are still unclear. It is pos-
sible that ligand-induced receptor conformational change triggers thereceptor binding from its stabilizer (deubiquitinating enzyme) to
destabilizer (ubiquitin E3 ligase). USP11 also deubiquitinates SUMO-
ubiquitin chains from PML (Wu et al., 2014), while the sumolytion of
LPA1 has not been discovered.
LPA1 is recognized as pro-inﬂammatory GPCR in the lung inﬂamma-
tory diseases (Tager et al., 2008; Zhao et al., 2011; Zhao et al., 2006). LPA
induced cytokine release in lung epithelial cells (Cummings et al., 2004;
Zhao et al., 2005; Saatian et al., 2006), leading to recruit neutrophil in-
ﬂux (He et al., 2009). Recent studies have shown that LPA1 interacts
with CD14, co-receptor of LPS (Zhao et al., 2011; Zhao et al., 2015). Un-
derstanding regulation of LPA1 stability may provide an advanced ther-
apeutic strategy to lessen inﬂammatory lung diseases by down-
regulating, but not completely inhibiting, LPA1 levels. The current
study shows that USP11 has pro-inﬂammatory effect in lung inﬂamma-
tory injury. This is contrast with the previous ﬁnding that USP11 nega-
tively regulates TNFα-induced cytokine release by targeting NF-κB
pathway in Hela cells (Sun et al., 2010). The controversial conclusion
may be due to using different cell types and stimuli. This study shows
that USP11 stabilizes LPA1, thus leading an increase in LPA1-CD14 com-
plex on the cell surface, which contributes LPS-induced signaling and
cytokine release in lung epithelial cells. This ﬁnding indicates that
targetingUSP11 attenuates endotoxin-induced inﬂammatory responses
in the murine model of lung injury.
Fig. 8.MX, an inhibitor of USP11, reduces LPA1 levels and lessens LPS-induced lung inﬂammation. a. MLE12 cells were treated with DMSO or MX (5 μM) for 1 h prior to LPA treatment
(5 μM, 30 min). Cell lysates were subjected to immunoprecipitation with an ubiquitin antibody, followed by LPA1 immunoblotting. Input lysates were analyzed by immunoblotting
with LPA1 and β-actin antibodies. b. MLE12 cells were treated with MX (5 μM) for 0–8 h. Cell lysates were analyzed by immunoblotting with LPA1 and β-actin antibodies. c. MLE12
cells were transfected with LPA1-V5 or LPA2-V5 plasmid, and then cells were treated with MX (0–10 μM) for 6 h. Cell lysates were analyzed by immunoblotting with antibodies to V5
and β-actin antibodies. d. MLE12 cells were treated with MX (5 μM, 6 h) prior to LPA treatment (5 μM, 10 min). Cell lysates were analyzed by p-Erk1&2, Erk1&2, p-p38 MAPK, p38
MAPK, p-I-κB, and β-actin antibodies. Representative immunoblots were from at least three independent times. e. HBEpCs were treated with MX (5 μM, 6 h) prior to LPA treatment
(1 μM, 3 h), and then cells were collected and IL-8 mRNA levels were examined by RT realtime PCR. f. HBEpCs were treated with MX (5 μM, 6 h) prior to LPS treatment (10 μg/ml,
3 h), and then cells were collected and IL-8 mRNA levels were examined by RT realtime PCR. g. MLE12 cells were treated with MX (5 μM, 6 h) prior to LPS treatment (10 μg/ml, 6 h),
and then cells were collected and KC mRNA levels were examined by RT realtime PCR. h–k. C57/BL6 mice (6–8/group) were i.t. administrated with MX (0.25 mg/kg body weight) for
1 h, and then followed by i.t. LPS (2 mg/kg body weight) for 24 h. BAL were collected and BAL protein levels were measured by protein assay (h), IL-6 (i) and KC (j) levels were
examined by Elisa. Lung tissues were ﬁxed and stained with H&E (k).
202 J. Zhao et al. / EBioMedicine 10 (2016) 195–203This study reveals molecular mechanisms by which Nedd4L and
USP11 regulate LPA1 stability and LPA1-mediated signaling, thus mod-
ulate LPA- or LPS-induced inﬂammatory responses. Destabilization of
LPA1 by inhibition or down-regulation of USP11 diminishes lung injury.
The anti-inﬂammatory effect of USP11 inhibitor may be beneﬁcial to
other diseases including inﬂammatory bowel disease. To develop
small molecules speciﬁc for destabilization of LPA1, future studies will
focus on drug throughput screening of small molecules to interrupt
the interaction between LPA1 and USP11 interaction, thereby leading
destabilization of LPA1 and lessening endotoxin-induced inﬂammatory
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